Latest News - Genentech

Monday, November 13, 2017 | Retina, Genentech

Genentech Makes Statement Following Release of Novartis' Brolucizumab Data

At the American Academy of Ophthalmology meeting in New Orleans, Novartis announced positive results from two phase 3 studies (HAWK and HARRIER) of brolucizumab versus Regeneron's aflibercept (Eyl…

Read the full story

Thursday, October 19, 2017 | Clinical Trials, Retina, AMD, Genentech

Genentech Completes Patient Enrollment In Phase 2 Study Evaluating A New Delivery System for Lucentis

Genentech has completed enrollment in the LADDER (Long Acting Delivery of Ranibizumab) trial, a phase 2, multicenter, randomized, active treatment-controlled clinical trial investigatin…

Read the full story

Monday, September 11, 2017 | Clinical Trials, Retina, AMD, Genentech

Genentech's Lampalizumab Fails Phase 3 Study for Geographic Atrophy

Genentech announced that the primary endpoint has not been met in Spectri, the first of two phase 3 studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the trea…

Read the full story

Friday, September 01, 2017 | Retina, Genentech

EURETINA 2017: Genentech Ophthalmology Data Highlights

Genentech released teh data it will be presenting at the European Society of Retina Specialists (EURETINA) meeting on September 7-10 in Barcelona. Below are key takeaways from the EURETINA 2017 stu…

Read the full story

Thursday, July 27, 2017 | Clinical Trials, Genentech

Genentech Announces Positive Phase 3 Results of Actemra for the Treatment of Giant Cell Arteritis

Genentech announced that data from the phase 3 GiACTA study, which evaluated Actemra (tocilizumab) in adult patients with GCA, were published in the July 27, 2017 issue of the New Engla…

Read the full story

Monday, May 22, 2017 | FDA Approval/Clearance, Genentech

FDA Approves Genentech’s Actemra for Giant Cell Arteritis

Genentech announced that the FDA has approved Actemra (tocilizumab) subcutaneous injection for the treatment of giant cell arteritis (GCA), a chronic and severe autoimmune condition. Actemra is the fi…

Read the full story

Monday, April 17, 2017 | FDA Approval/Clearance, Retina, Genentech

FDA Approves Lucentis for All Forms of Diabetic Retinopathy

Genentech announced that the FDA has approved Lucentis (ranibizumab) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. With this approval, Lucentis becomes the first and only FDA-…

Read the full story

Tuesday, April 04, 2017 | Clinical Trials, Genentech

Genentech Presents Positive Phase 3 Results for Giant Cell Arteritis

Genentech presented for the first time its results from GiACTA, a phase 3 study which evaluated Actemra (tocilizumab) in people with giant cell arteritis (GCA), to an ophthalmology audience. The abstr…

Read the full story

Thursday, February 02, 2017 | Clinical Trials, AMD, Genentech

Genentech Completes Patient Enrollment in Two Large Phase 3 Studies for Lampalizumab

Genentech has completed enrollment in two large phase 3 clinical trials, Chroma and Spectri, investigating the efficacy and safety of lampalizumab in reducing the progression of geographic atrophy (GA…

Read the full story

Monday, January 30, 2017 | Product Releases, AMD, Genentech

Lucentis 0.5 mg Prefilled Syringe Now Available to Order in the US

Ophthalmologists across the United States can now order the Lucentis 0.5 mg prefilled syringe (PFS). The PFS is a new method of administering Lucentis to treat people with wet age-related macular dege…

Read the full story

Tuesday, January 24, 2017 | Clinical Trials, Genentech

FDA Grants Priority Review for Genentech’s Actemra Supplemental Biologics License Application for Giant Cell Arteritis

Genentech announced that the FDA has accepted the company’s supplemental biologics license application for Actemra (tocilizumab) for the treatment of giant cell arteritis (GCA). The FDA also gra…

Read the full story

Thursday, January 05, 2017 | FDA Approval/Clearance, Genentech

FDA Approves Lucentis for Myopic Choroidal Neovascularization

Genentech announced that the FDA has approved Lucentis (ranibizumab) 0.5 mg for the treatment of patients with myopic choroidal neovascularization (mCNV). Lucentis is the first FDA-approved anti-vascu…

Read the full story

Monday, November 14, 2016 | Medical Studies, Genentech

Phase 3 Study Shows Genentech's Actemra is Superior to Steroids Alone in Maintaining Steroid-Free Remission for People with Giant Cell Arteritis

Genentech announced positive results from the phase 3 GiACTA study, which evaluated Actemra (tocilizumab) in people with giant cell arteritis (GCA), according to a company news release. GiACTA met …

Read the full story

Friday, October 14, 2016 | Product Releases, Genentech

FDA Approves Genentech’s Lucentis (Ranibizumab) Prefilled Syringe

Genentech announced that the FDA approved the Lucentis (ranibizumab) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, the 0.5 mg PFS is appr…

Read the full story

Tuesday, October 11, 2016 | Clinical Trials, Retina, Genentech

FDA Grants Priority Review to Genentech’s Lucentis Supplemental Biologics License Application for Myopic Choroidal Neovascularization

Genentech announced that the FDA has accepted a supplemental Biologics License Application (sBLA) and granted priority review for Lucentis (ranibizumab) for the treatment of myopic choroidal neovascul…

Read the full story
Load More